We are excited to announce that Eagle IP will be participating as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Fall Conference in San Francisco. Our President and Managing Director, Ms. Jennifer Che, is a distinguished speaker at the event. Her talk, titled China Patent Landscape, will provide a brief overview of top China IP issues for life sciences companies and provide some strategies for how to navigate such issues (e.g., AI, post-filing data, PTA/PTE, patent linkage, export controls, and more).

Organized by Life Sciences Intellectual Property Review, this event will take place October 21-22, 2025.


Eagle IP will also be in the greater Washington DC area from October 27-31, 2025. Ms. Jennifer Che will be attending Life Sciences Masters™ 2025 (organized by IP Watchdog) in Ashburn, Virginia from October 27-29, and AIPLA 2025 Annual Meeting (organized by American Intellectual Property Law Association) in Washington DC from Oct 29-31.

If you won’t be able to attend LSPN or AIPLA, but will be in San Francisco or the Washington DC area and would like to schedule a meeting, please let us know. We look forward to seeing some of you in San Francisco and Washington DC later this month!

Our Past Events

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

Compositions Limited by Use: A Cautionary Tale

26 October 2022
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

Updates on Hong Kong Patents Examination Guidelines in 2024

29 February 2024
The Intellectual Property Department of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKIPD) has recently made several updates to the Hong Kong Patents Examination Guidelines, effective from 26 January, 2024. These changes mainly clarify and reflect the Registry’s current practices regarding patent examination for Standard Patent (R) […]

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

10 November 2023
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]
Top crossarrow-right